Amneal Pharmaceuticals Debt to Equity

Amneal Pharmaceuticals's debt-to-equity ratio stands at 84.54. That is above the Healthcare sector average of 0.27. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Amneal Pharmaceuticals sits higher the Healthcare benchmark (0.27) with a debt-to-equity ratio of 84.54. That is roughly 31738.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 84.54 is attractive depends on Amneal Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Amneal Pharmaceuticals's debt-to-equity ratio evolved across reporting periods, while the comparison chart places AMRX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, debt-to-equity ratio is commonly used to spot outliers. Amneal Pharmaceuticals's reading of 84.54 (sector avg 0.27) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.